Research programme: T-cell therapies- Triumvira
Latest Information Update: 05 Jul 2016
At a glance
- Originator Triumvira
- Class Cell therapies
- Mechanism of Action B-cell maturation antigen modulators; CD19 antigen modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Preclinical B cell lymphoma; Leukaemia; Multiple myeloma; Ovarian cancer
- Research Solid tumours